Cabaletta Bio (CABA)

• Market cap: $457M
• 1 day: -6.98%
• 5 days: -11.11%
• 1 month: -14.89%
• 3 months: -12.5%
• 6 months: 17.15%
• Year to date: 26.7%
• 1 year: 44.33%
• 5 years: -63.87%
• 10 years: -72%
• Sector: Healthcare
• Industry: Biotechnology

About: Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Employees: 158